Journey Medical Co. (NASDAQ:DERM - Get Free Report) dropped 5.3% on Tuesday . The company traded as low as $3.99 and last traded at $4.11. Approximately 40,497 shares were traded during trading, a decline of 20% from the average daily volume of 50,699 shares. The stock had previously closed at $4.34.
Journey Medical Trading Down 2.7 %
The company has a debt-to-equity ratio of 1.81, a current ratio of 1.38 and a quick ratio of 1.03. The firm's fifty day moving average is $5.08 and its 200-day moving average is $5.25. The firm has a market cap of $83.56 million, a price-to-earnings ratio of -4.26 and a beta of 1.00.
Institutional Trading of Journey Medical
Several hedge funds have recently modified their holdings of the stock. PVG Asset Management Corp grew its holdings in Journey Medical by 5.7% in the third quarter. PVG Asset Management Corp now owns 167,545 shares of the company's stock worth $947,000 after purchasing an additional 9,005 shares during the period. Geode Capital Management LLC grew its stake in shares of Journey Medical by 13.5% in the 3rd quarter. Geode Capital Management LLC now owns 108,435 shares of the company's stock valued at $613,000 after buying an additional 12,882 shares during the period. ORG Wealth Partners LLC bought a new stake in Journey Medical in the 3rd quarter valued at about $110,000. TMD Wealth Management LLC acquired a new position in Journey Medical during the 2nd quarter worth approximately $65,000. Finally, Kovitz Investment Group Partners LLC bought a new position in Journey Medical in the third quarter worth approximately $66,000. Institutional investors own 7.25% of the company's stock.
About Journey Medical
(
Get Free Report)
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.
See Also
Before you consider Journey Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Journey Medical wasn't on the list.
While Journey Medical currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
